Cargando…

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

BACKGROUND: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779784/ https://www.ncbi.nlm.nih.gov/pubmed/35091386 http://dx.doi.org/10.1016/j.jns.2022.120155

Ejemplares similares

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
por: Achiron, Anat, et al.
Publicado: (2021)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
por: Gurevich, Michael, et al.
Publicado: (2022)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
por: Achiron, Anat, et al.
Publicado: (2023)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents
por: Gurevich, Michael, et al.
Publicado: (2022)

Longitudinal relationships between disability and gait characteristics in people with MS
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
por: Achiron, Anat, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis
por: Menascu, Shay, et al.
Publicado: (2023)

Motoric cognitive risk syndrome in people with multiple sclerosis: prevalence and correlations with disease-related factors
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients
por: Menascu, Shay, et al.
Publicado: (2020)

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
por: Gurevich, Michael, et al.
Publicado: (2015)

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a
por: Menascu, Shay, et al.
Publicado: (2021)

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
por: Achiron, Anat, et al.
Publicado: (2021)

A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort
por: Kalron, Alon, et al.
Publicado: (2015)

Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
por: Achiron, Anat, et al.
Publicado: (2013)

The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study
por: Kalron, Alon, et al.
Publicado: (2022)

Cognitive function in multiple sclerosis: A long-term look on the bright side
por: Harel, Yermi, et al.
Publicado: (2019)

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study
por: Harari, Gil, et al.
Publicado: (2023)

Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2012)

Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
por: Achiron, A., et al.
Publicado: (2004)

Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey
por: Kalron, Alon, et al.
Publicado: (2021)

Optical Coherence Tomography Is Associated With Cognitive Impairment in Multiple Sclerosis
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis
por: Kalron, Alon, et al.
Publicado: (2016)

Cytokine prediction of mortality in COVID19 patients
por: Mandel, Mathilda, et al.
Publicado: (2020)

Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis
por: Levi, Izhak, et al.
Publicado: (2021)

Unique Gene Expression Patterns in Human T-cell Lines Generated from Multiple Sclerosis Patients by Stimulation with a Synthetic MOG Peptide
por: Mandel, Mathilda, et al.
Publicado: (2005)

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

An Immersive Virtual Kitchen Training System for People with Multiple Sclerosis: A Development and Validation Study
por: Pau, Massimiliano, et al.
Publicado: (2023)

Unique features of central neuropathic pain in multiple sclerosis: Results of a cluster analysis
por: Rivel, Michal, et al.
Publicado: (2022)

Association Between White Matter Microstructure and Verbal Fluency in Patients With Multiple Sclerosis
por: Blecher, Tal, et al.
Publicado: (2019)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells
por: Gurevich, Michael, et al.
Publicado: (2009)

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis
por: Volfovitch, Yuval, et al.
Publicado: (2022)

Prefrontal hemodynamics during forward and backward walking, with and without a cognitive task, in people with multiple sclerosis
por: KUPCHENKO, Yana, et al.
Publicado: (2023)

Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a
por: Flechter, Shlomo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_c7f32pfogvr7r1vbtds9hctln4